Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.
The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.
Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.
Sensei Biotherapeutics announced the FDA's clearance of its IND application for SNS-101, a VISTA-blocking antibody, enabling a Phase 1/2 clinical trial for patients with solid tumors. This key milestone is expected to significantly impact cancer treatment. The trial will assess SNS-101's safety, tolerability, pharmacokinetics, and efficacy, both alone and combined with Regeneron’s Libtayo® (cemiplimab). The initial patient dosing is anticipated in mid-2023. Preclinical data suggest SNS-101's promising potential to inhibit tumor growth and enhance PD-1 blockade effects, while maintaining better pharmacokinetics and reducing cytokine release syndrome risk.
Sensei Biotherapeutics (Nasdaq: SNSE) presented new preclinical data on its SNS-103 program at the AACR Annual Meeting 2023, focusing on targeting CD39, an enzyme linked to an immunosuppressive tumor microenvironment. The data suggests that SNS-103, a conditionally active monoclonal antibody, selectively binds to CD39 in low pH conditions typical of tumors, potentially improving anti-tumor immunity by preserving extracellular ATP and inhibiting adenosine generation.
The poster presentation highlighted the selection of 8 antibodies for further optimization from a panel of 83, with a lead product candidate expected to be selected in 2023. This advancement could position Sensei favorably within the immuno-oncology sector.
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in a panel discussion titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET. The company specializes in developing next-generation therapeutics for cancer patients through its TMAb™ platform.
Sensei's lead candidate is SNS-101, designed to inhibit T cell suppression in the tumor microenvironment. The company is also advancing SNS-102, targeting VSIG-4, and SNS-103, which targets ENTPDase1, also known as CD39. For more information, visit www.senseibio.com.
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (Nasdaq: SNSE), an immuno-oncology firm, announced that its CEO, John Celebi, will participate in a panel on 'Novel Approaches in Immunotherapy' at the Cantor Fitzgerald's Future of Oncology Virtual Symposium on April 3rd at 10:00 a.m. ET.
Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients using its TMAb™ platform. The lead candidate is SNS-101, targeting VISTA in the tumor microenvironment. Other candidates include SNS-102 and SNS-103, which target VSIG-4 and ENTPDase1, respectively. For more details, visit www.senseibio.com.
Sensei Biotherapeutics (Nasdaq: SNSE) announced the submission of an Investigational New Drug (IND) application for its lead candidate, SNS-101, aimed at treating solid tumors through VISTA blockade. The company has formed partnerships with Regeneron, the National Cancer Institute, and Washington University to bolster development. Sensei expects to advance a second TMAb™ program to IND-enabling studies. The company reported a cash position of $107.1 million and projects a runway into the second half of 2025. However, the net loss increased to $48.6 million in 2022, up from $36.8 million in 2021.
Sensei Biotherapeutics (NASDAQ: SNSE) announced on March 21, 2023, the submission of an Investigational New Drug (IND) application to the FDA for SNS-101, a VISTA-blocking antibody targeting solid tumors. This therapy is designed to selectively inhibit the VISTA checkpoint, which suppresses T cell activity, potentially enhancing anti-tumor responses. Preclinical data indicate SNS-101's efficacy as a monotherapy and in combination with PD-1 blockade, while minimizing poor pharmacokinetics and cytokine release syndrome risks. Sensei aims to address solid cancers with this innovative therapeutic approach.
Sensei Biotherapeutics (NASDAQ: SNSE) will unveil new preclinical data on SNS-103, a monoclonal antibody targeting CD39, at the AACR Annual Meeting 2023 in Orlando from April 14-19, 2023. The presentation titled 'Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment' is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM ET.
Sensei aims to develop therapeutics that activate immune responses against tumors utilizing its TMAb™ platform, and SNS-103 is part of its ongoing research in immune-oncology.
BOSTON, March 7, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced the adoption of a limited duration stockholder rights agreement to protect stockholder interests. This measure is aimed at preventing any entity from gaining control without appropriately compensating all stockholders. Each stockholder will receive one preferred share purchase right for each outstanding share of common stock, effective March 17, 2023. The rights will become exercisable if an acquiring person owns 10% or more of the stock without Company approval. This plan will expire on March 7, 2024. Sensei aims to ensure its Board can make informed decisions about control attempts.
Sensei Biotherapeutics (Nasdaq: SNSE) is set to present at Oppenheimer’s 33rd Annual Healthcare Conference on March 13, 2023. The presentation will begin at 8:00 a.m. ET and be accessible via a webcast on the company’s website. The webcast replay will be available for around 90 days after the event.
Sensei Biotherapeutics focuses on developing next-generation immuno-oncology therapeutics for cancer treatment, with its lead candidate being SNS-101, designed to target the VISTA checkpoint within tumor microenvironments. The company also works on candidates SNS-102 and SNS-103, aimed at different immunosuppressive signals.
Sensei Biotherapeutics (NASDAQ: SNSE) presented preclinical data on SNS-101, a VISTA-blocking antibody, revealing its potential to enhance anti-tumor effects while reducing risks associated with other VISTA antibodies. The new crystal structure data shows that SNS-101 effectively blocks the interaction between VISTA and PSGL-1 in a pH-dependent manner. Preclinical studies indicate a decreased risk of cytokine release syndrome and improved pharmacokinetics. The company plans to submit an IND application for SNS-101 by April 2023, with a Phase 1/2 trial expected to begin later in the year, pending regulatory approval.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
